Experimental vaccine trains body to fight advanced cancers
NCT ID NCT00722228
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a personalized vaccine made from a patient's own tumor cells or donor cells. The cells are modified and killed in the lab, then injected under the skin to train the immune system to attack the cancer. The study includes 50 adults with metastatic melanoma, breast, ovarian, colorectal, gastric, lung, or kidney cancer who have already tried chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized whole-cell cancer vaccine (irradiated, DNP-conjugated tumor cells)
What this could lead to
If it works, this could offer a new way to stimulate the immune system against advanced cancers, potentially prolonging survival in patients who have run out of options.
What could go wrong
This is an early-phase (1/2) trial with only 50 participants, so results may not apply broadly. The vaccine may not boost immunity enough to shrink tumors or extend life, and side effects from immune activation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hadassah Medical Organization
RECRUITINGJerusalem, 91120, Israel
Contact